Chen, Peiru; Wang, Dali; Wang, Yuyan; Zhang, Lei; Wang, Qiwei; Liu, Lanxia; Li, Jiahe; Sun, Xin; Ren, Mengqi; Wang, Ruoxuan; Fang, Yang; Zhao, Jean J.; Zhang, Ke published the artcile< Maximizing TLR9 Activation in Caner Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids>, Safety of 1,2-Di(pyridin-2-yl)disulfane, the main research area is cancer immunotherapy dual adjuvanted spherical nucleic acid TLR9; CpG oligonucleotides; DNA amphiphiles; cancer vaccines; spherical nucleic acids.
Nucleic-acid-based immune adjuvants have been extensively investigated for the design of cancer vaccines. However, nucleic acids often require the assistance of a carrier system to improve cellular uptake. Yet, such systems are prone to carrier-associated adaptive immunity, leading to difficulties in a multidose treatment regimen. Here, we demonstrate that a spherical nucleic acid (SNA)-based self-adjuvanting system consisting of phosphodiester oligonucleotides and vitamin E can function as a potent anticancer vaccine without a carrier. The two functional modules work synergistically, serving as each other′s delivery vector to enhance toll-like receptor 9 activation. The vaccine rapidly enters cells carrying OVA model antigens, which enables efficient activation of adaptive immunity in vitro and in vivo. In OVA-expressing tumor allograft models, both prophylactic and therapeutic vaccinations significantly retard tumor growth and prolong animal survival. Furthermore, the vaccinations were also able to reduce lung metastasis in a B16F10-OVA model.
Nano Letters published new progress about Adaptive immunity. 2127-03-9 belongs to class pyridine-derivatives, and the molecular formula is C10H8N2S2, Safety of 1,2-Di(pyridin-2-yl)disulfane.